RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Total Non-current Liabilities
All obligations due after more than one year.
RenovoRx, Inc.NASDAQ: RNXT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 30.5% from a year ago
Total non-current liabilities stood at $779K at the end of Q1 FY2026, down 30.5% from a year earlier and up 9.6% from the prior quarter.
Context
- Total non-current liabilities amounted to 5.6% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -30.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 711K USD
- Year-over-year change
- -58.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 711K | -58.9% |
| FY2024 | 2024-12-31 | 1.73M | -47.4% |
| FY2023 | 2023-12-31 | 3.29M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 total non-current liabilities of $779K is the 4th highest of the 6 companies compared; the peer median is $1.24M.
- Its year-over-year change of -30.5% is the 4th highest of 6, against a peer median of -23.9%.
- Total non-current liabilities amounts to 5.6% of total assets for RNXT, versus a peer median of 3.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $64.63M | -7.9% | -22.7% | 60.2% | |
| Mar 2026 | $3.33M | -23.9% | -32.3% | 17.4% | |
| Mar 2026 | $1.24M | -33.6% | +82.5% | 3.5% | |
| Mar 2026 | $779K | -30.5% | — | 5.6% | |
| Mar 2026 | $327K | +82.7% | — | 2.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding RNXT) | $1.24M | -23.9% | -22.7% | 3.5% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.